Advisors Capital Management LLC Boosts Holdings in Solventum Corporation $SOLV

Key Points

• Advisors Capital Management LLC increased its stake in Solventum Corporation by 43.6% during the first quarter, bringing their total holdings to 44,901 shares valued at approximately $3.41 million.
• In recent analyst ratings, Piper Sandler set a new price objective of $94.00, while Morgan Stanley raised its target to $103.00, indicating a generally positive outlook on the stock.
• Solventum reported strong financial results, with an earnings per share of $1.69 for the recent quarter, exceeding analyst expectations and marking a year-over-year increase in revenue of 3.8%.

Advisors Capital Management LLC raised its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 43.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,901 shares of the company's stock after buying an additional 13,625 shares during the period. Advisors Capital Management LLC's holdings in Solventum were worth $3,414,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Trian Fund Management L.P. lifted its holdings in shares of Solventum by 18.8% during the fourth quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock worth $559,054,000 after purchasing an additional 1,336,564 shares during the period. Independent Franchise Partners LLP lifted its holdings in shares of Solventum by 263.1% during the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company's stock worth $442,608,000 after purchasing an additional 4,217,570 shares during the period. Davis Selected Advisers lifted its holdings in shares of Solventum by 0.8% during the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock worth $402,110,000 after purchasing an additional 41,524 shares during the period. Boston Partners raised its stake in Solventum by 101.3% during the first quarter. Boston Partners now owns 3,361,973 shares of the company's stock worth $255,554,000 after buying an additional 1,691,565 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Solventum by 3.3% during the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock worth $137,456,000 after buying an additional 58,373 shares during the last quarter.

Solventum Stock Performance

SOLV traded up $0.29 during midday trading on Thursday, reaching $74.36. The company had a trading volume of 300,405 shares, compared to its average volume of 1,082,307. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock has a market cap of $12.89 billion, a PE ratio of 34.42, a P/E/G ratio of 3.02 and a beta of 0.53. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92. The business has a 50-day moving average price of $73.01 and a two-hundred day moving average price of $72.48.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company's quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, sell-side analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on SOLV. Wells Fargo & Company lifted their price target on shares of Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a research note on Monday. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. KeyCorp initiated coverage on shares of Solventum in a research report on Friday, June 6th. They issued a "sector weight" rating for the company. Jefferies Financial Group initiated coverage on shares of Solventum in a research report on Thursday, September 11th. They issued a "hold" rating and a $80.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Solventum from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $85.44.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.